388 related articles for article (PubMed ID: 13129923)
1. Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases.
Billich A; Bornancin F; Dévay P; Mechtcheriakova D; Urtz N; Baumruker T
J Biol Chem; 2003 Nov; 278(48):47408-15. PubMed ID: 13129923
[TBL] [Abstract][Full Text] [Related]
2. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2.
Paugh SW; Payne SG; Barbour SE; Milstien S; Spiegel S
FEBS Lett; 2003 Nov; 554(1-2):189-93. PubMed ID: 14596938
[TBL] [Abstract][Full Text] [Related]
3. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform.
Liu H; Sugiura M; Nava VE; Edsall LC; Kono K; Poulton S; Milstien S; Kohama T; Spiegel S
J Biol Chem; 2000 Jun; 275(26):19513-20. PubMed ID: 10751414
[TBL] [Abstract][Full Text] [Related]
4. FTY720 inhibits ceramide synthases and up-regulates dihydrosphingosine 1-phosphate formation in human lung endothelial cells.
Berdyshev EV; Gorshkova I; Skobeleva A; Bittman R; Lu X; Dudek SM; Mirzapoiazova T; Garcia JG; Natarajan V
J Biol Chem; 2009 Feb; 284(9):5467-77. PubMed ID: 19119142
[TBL] [Abstract][Full Text] [Related]
5. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720.
Zemann B; Kinzel B; Müller M; Reuschel R; Mechtcheriakova D; Urtz N; Bornancin F; Baumruker T; Billich A
Blood; 2006 Feb; 107(4):1454-8. PubMed ID: 16223773
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological activity of sphingosine kinase 2 selective inhibitors.
Raje MR; Knott K; Kharel Y; Bissel P; Lynch KR; Santos WL
Bioorg Med Chem; 2012 Jan; 20(1):183-94. PubMed ID: 22137932
[TBL] [Abstract][Full Text] [Related]
7. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720.
Allende ML; Sasaki T; Kawai H; Olivera A; Mi Y; van Echten-Deckert G; Hajdu R; Rosenbach M; Keohane CA; Mandala S; Spiegel S; Proia RL
J Biol Chem; 2004 Dec; 279(50):52487-92. PubMed ID: 15459201
[TBL] [Abstract][Full Text] [Related]
8. Activation of sphingosine kinase 2 is an endogenous protective mechanism in cerebral ischemia.
Pfeilschifter W; Czech-Zechmeister B; Sujak M; Mirceska A; Koch A; Rami A; Steinmetz H; Foerch C; Huwiler A; Pfeilschifter J
Biochem Biophys Res Commun; 2011 Sep; 413(2):212-7. PubMed ID: 21872577
[TBL] [Abstract][Full Text] [Related]
9. Hypoxic preconditioning-induced cerebral ischemic tolerance: role of microvascular sphingosine kinase 2.
Wacker BK; Park TS; Gidday JM
Stroke; 2009 Oct; 40(10):3342-8. PubMed ID: 19644058
[TBL] [Abstract][Full Text] [Related]
10. Effect of alkyl chain length on sphingosine kinase 2 selectivity.
Knott K; Kharel Y; Raje MR; Lynch KR; Santos WL
Bioorg Med Chem Lett; 2012 Nov; 22(22):6817-20. PubMed ID: 22321213
[TBL] [Abstract][Full Text] [Related]
11. Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues.
Don AS; Martinez-Lamenca C; Webb WR; Proia RL; Roberts E; Rosen H
J Biol Chem; 2007 May; 282(21):15833-42. PubMed ID: 17400555
[TBL] [Abstract][Full Text] [Related]
12. Effects of phosphorylation of immunomodulatory agent FTY720 (fingolimod) on antiproliferative activity against breast and colon cancer cells.
Nagaoka Y; Otsuki K; Fujita T; Uesato S
Biol Pharm Bull; 2008 Jun; 31(6):1177-81. PubMed ID: 18520051
[TBL] [Abstract][Full Text] [Related]
13. Role of the sphingosine metabolism pathway on neurons against experimental cerebral ischemia in rats.
Hasegawa Y; Suzuki H; Altay O; Rolland W; Zhang JH
Transl Stroke Res; 2013 Oct; 4(5):524-32. PubMed ID: 24187597
[TBL] [Abstract][Full Text] [Related]
14. The Intra-nuclear SphK2-S1P Axis Facilitates M1-to-M2 Shift of Microglia via Suppressing HDAC1-Mediated KLF4 Deacetylation.
Ji J; Wang J; Yang J; Wang XP; Huang JJ; Xue TF; Sun XL
Front Immunol; 2019; 10():1241. PubMed ID: 31214192
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability.
Sanchez T; Estrada-Hernandez T; Paik JH; Wu MT; Venkataraman K; Brinkmann V; Claffey K; Hla T
J Biol Chem; 2003 Nov; 278(47):47281-90. PubMed ID: 12954648
[TBL] [Abstract][Full Text] [Related]
16. Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720.
Kharel Y; Lee S; Snyder AH; Sheasley-O'neill SL; Morris MA; Setiady Y; Zhu R; Zigler MA; Burcin TL; Ley K; Tung KS; Engelhard VH; Macdonald TL; Pearson-White S; Lynch KR
J Biol Chem; 2005 Nov; 280(44):36865-72. PubMed ID: 16093248
[TBL] [Abstract][Full Text] [Related]
17. Functional characterization of sphingosine 1-phosphate receptor agonist in human endothelial cells.
Butler J; Lana D; Round O; LaMontagne K
Prostaglandins Other Lipid Mediat; 2004 Jan; 73(1-2):29-45. PubMed ID: 15165029
[TBL] [Abstract][Full Text] [Related]
18. Targeting sphingosine-1-phosphate in hematologic malignancies.
Stevenson CE; Takabe K; Nagahashi M; Milstien S; Spiegel S
Anticancer Agents Med Chem; 2011 Nov; 11(9):794-8. PubMed ID: 21707492
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of sphingosine kinase substrates as sphingosine-1-phosphate receptor prodrugs.
Foss FW; Mathews TP; Kharel Y; Kennedy PC; Snyder AH; Davis MD; Lynch KR; Macdonald TL
Bioorg Med Chem; 2009 Aug; 17(16):6123-36. PubMed ID: 19632123
[TBL] [Abstract][Full Text] [Related]
20. FTY720 postconditions isolated perfused heart by a mechanism independent of sphingosine kinase 2 and different from S1P or ischemic postconditioning.
Vessey DA; Li L; Imhof I; Honbo N; Karliner JS
Med Sci Monit Basic Res; 2013 Apr; 19():126-32. PubMed ID: 23567658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
